Completed PHASE1 INTERVENTIONAL 1-arm NCT02808650

Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

A Phase 1 Study of LY2606368 (Prexasertib Mesylate Monohydrate) a CHK1/2 Inhibitor, in Pediatric Patients With Recurrent or Refractory Solid Tumors, Including CNS Tumors

Sponsor: Children's Oncology Group

Conditions Childhood Solid Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Primary Central Nervous System Neoplasm Refractory Malignant Solid Neoplasm Refractory Primary Central Nervous System Neoplasm

Interventions Laboratory Biomarker Analysis Pharmacokinetic (PK) study Prexasertib

Updated 20 times since 2017 Last updated: Dec 18, 2023 Started: Feb 27, 2017 Primary completion: Dec 31, 2019 Completion: Mar 31, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02808650, this PHASE1 trial focuses on Childhood Solid Neoplasm and Recurrent Malignant Solid Neoplasm and remains completed. Sponsored by Children's Oncology Group, it has been updated 20 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

20 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2024 — Jul 2024 [monthly]

Completed PHASE1
Oct 2023 — Jan 2024 [monthly]

Completed PHASE1

▶ Show 15 earlier versions

May 2021 — Oct 2023 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jan 2021 — May 2021 [monthly]

Active Not Recruiting PHASE1
Jul 2020 — Jan 2021 [monthly]

Active Not Recruiting PHASE1
Jun 2020 — Jul 2020 [monthly]

Active Not Recruiting PHASE1
Aug 2019 — Jun 2020 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
May 2019 — Aug 2019 [monthly]

Recruiting PHASE1
Mar 2019 — May 2019 [monthly]

Recruiting PHASE1
Sep 2018 — Mar 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE1
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE1
Jul 2017 — Dec 2017 [monthly]

Recruiting PHASE1
Jun 2017 — Jul 2017 [monthly]

Recruiting PHASE1
Mar 2017 — Jun 2017 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Feb 2017 — Mar 2017 [monthly]

Not Yet Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Children's Oncology Group
National Cancer Institute (NCI)

Data source: Children's Oncology Group

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Aurora, United States , Birmingham, United States , Boston, United States , Chicago, United States , Cincinnati, United States , Houston, United States , Indianapolis, United States , Los Angeles, United States and 11 more locations